{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:17:00Z","timestamp":1793013420621,"version":"4.5.0"},"reference-count":450,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":204,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013276","name":"Interreg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.addr.2020.07.019","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T01:35:46Z","timestamp":1595813746000},"page":"4-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":379,"special_numbering":"C","title":["Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting"],"prefix":"10.1016","volume":"159","author":[{"given":"Josefin","family":"Soppert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lehrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Noels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2018","key":"10.1016\/j.addr.2020.07.019_bb0005","first-page":"1736","article-title":"Causes of death collaborators, global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association","volume":"133","author":"Writing Group Members","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0015","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.2538","article-title":"Atherosclerosis: current pathogenesis and therapeutic options","volume":"17","author":"Weber","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","article-title":"Reducing the global burden of cardiovascular disease, Part 1: the epidemiology and risk factors","volume":"121","author":"Joseph","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1515\/bchm2.1910.67.2.174","article-title":"\u00dcber den Gehalt normaler und atheromat\u00f6ser Aorten an Cholesterol and Cholesterinester Zeitschrift","volume":"67","author":"Windaus","year":"1910","journal-title":"Physiol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0030","first-page":"1","article-title":"\u00dcber experimentelle Cholesterinsteatose und ihre Bedeutung f\u00fcr die Entstehung einiger pathologischer Prozesse","volume":"24","author":"Anitschkow","year":"1913","journal-title":"Zentralbl. Allg. Pathol."},{"key":"10.1016\/j.addr.2020.07.019_bb0035","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archinte.1939.00190040016002","article-title":"Angina pectoris in hereditary xanthomatosis","volume":"64","author":"M\u00fcller","year":"1939","journal-title":"Arch. Intern. Med. (Chic)"},{"key":"10.1016\/j.addr.2020.07.019_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","article-title":"Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study","volume":"55","author":"Kannel","year":"1961","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0045","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/oxfordjournals.aje.a114480","article-title":"The diet and 15-year death rate in the seven countries study","volume":"124","author":"Keys","year":"1986","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.addr.2020.07.019_bb0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High-density lipoprotein as a protective factor against coronary heart-disease - Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-90-1-85","article-title":"Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study","volume":"90","author":"Kannel","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0065","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/ATVBAHA.111.240705","article-title":"Regulation of lipid droplet cholesterol efflux from macrophage foam cells","volume":"32","author":"Ouimet","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0070","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/138945011795378522","article-title":"ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis","volume":"12","author":"Ye","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2020.07.019_bb0075","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1194\/jlr.M600539-JLR200","article-title":"Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI","volume":"48","author":"Yancey","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0080","doi-asserted-by":"crossref","first-page":"24020","DOI":"10.1074\/jbc.R114.583658","article-title":"Molecular mechanisms of cellular cholesterol efflux","volume":"289","author":"Phillips","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0085","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/01.ATV.0000229218.97976.43","article-title":"Scavenger receptors in atherosclerosis: beyond lipid uptake","volume":"26","author":"Moore","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri2675","article-title":"Macrophage death and defective inflammation resolution in atherosclerosis","volume":"10","author":"Tabas","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2020.07.019_bb0095","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.07.019_bb0100","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1172\/JCI118853","article-title":"Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma","volume":"98","author":"Palinski","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0105","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nm876","article-title":"Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry betweeiujkNJn Streptococcus pneumoniae and oxidized LDL","volume":"9","author":"Binder","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0110","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1073\/pnas.92.9.3893","article-title":"T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein","volume":"92","author":"Stemme","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and Inflammation in Atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0120","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1084\/jem.20092243","article-title":"Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis","volume":"207","author":"Hermansson","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0125","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/CIRCULATIONAHA.118.034076","article-title":"Low-density lipoprotein-reactive T cells regulate plasma cholesterol levels and development of atherosclerosis in humanized hypercholesterolemic mice","volume":"138","author":"Gistera","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jth.13925","article-title":"Oxidized low-density lipoprotein in inflammation-driven thrombosis","volume":"16","author":"Obermayer","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.addr.2020.07.019_bb0135","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jacbts.2019.04.005","article-title":"Platelet Acetyl-CoA carboxylase phosphorylation: a risk stratification marker that reveals platelet-lipid interplay in coronary artery disease patients","volume":"4","author":"Kautbally","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.addr.2020.07.019_bb0140","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2018-02-831503","article-title":"AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation","volume":"132","author":"Lepropre","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.addr.2020.07.019_bb0145","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb0150","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb0155","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb0160","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2018.4041","article-title":"Challenges in interpreting the lipid-lowering trials: biology vs ecology","volume":"319","author":"Navar","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb0165","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0170","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011433","article-title":"Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: observations from the Framingham Study Over 35 Years","volume":"8","author":"Duncan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2020.07.019_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012924","article-title":"Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem","volume":"8","author":"Gidding","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2020.07.019_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009778","article-title":"Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein B lipoproteins earlier in life","volume":"7","author":"Robinson","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2020.07.019_bb0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000067","article-title":"The composition and metabolism of large and small LDL","volume":"25","author":"Diffenderfer","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb0190","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","article-title":"Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study","volume":"34","author":"Hoogeveen","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/ATVBAHA.113.302401","article-title":"New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the Multi-ethnic Study of Atherosclerosis","volume":"34","author":"Tsai","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0200","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1194\/jlr.M500161-JLR200","article-title":"A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes","volume":"46","author":"Davidsson","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0205","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehy319","article-title":"Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths","volume":"39","author":"Ruuth","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb0210","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb0215","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Illuminate investigators, effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0220","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb0225","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Aim-High Investigators","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0230","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Outcomes investigators dal, effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0235","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/ATVBAHA.109.186031","article-title":"Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function","volume":"29","author":"Davidson","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0240","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/CIRCULATIONAHA.117.031276","article-title":"High-density lipoprotein subspecies defined by presence of apolipoprotein C-III and incident coronary heart disease in four cohorts","volume":"137","author":"Jensen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0245","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MOL.0000000000000571","article-title":"HDL modification: recent developments and their relevance to atherosclerotic cardiovascular disease","volume":"30","author":"Wilkins","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb0250","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1161\/ATVBAHA.119.312880","article-title":"Reciprocal multifaceted interaction between HDL (high-density lipoprotein) and myocardial infarction","volume":"39","author":"Sposito","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0255","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/CIRCULATIONAHA.116.025678","article-title":"Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)","volume":"135","author":"Khera","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0260","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0265","unstructured":"Servier, SMART Servier Medical ART. 2020 [Available from: https:\/\/smart.servier.com\/]."},{"key":"10.1016\/j.addr.2020.07.019_bb0270","doi-asserted-by":"crossref","first-page":"47890","DOI":"10.1074\/jbc.M306258200","article-title":"Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly","volume":"278","author":"Yamauchi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0275","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/01.ATV.0000142804.27420.5b","article-title":"Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease","volume":"24","author":"Brewer","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0280","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0005-2760(91)90062-M","article-title":"Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins","volume":"1084","author":"Jonas","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2020.07.019_bb0285","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1210\/er.2001-0037","article-title":"The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues","volume":"24","author":"Rigotti","year":"2003","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.addr.2020.07.019_bb0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature01250","article-title":"Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis","volume":"421","author":"Martinez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.07.019_bb0295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0300","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11883-011-0175-2","article-title":"Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport","volume":"13","author":"Annema","year":"2011","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.addr.2020.07.019_bb0305","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/01.ATV.14.5.707","article-title":"Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution","volume":"14","author":"Brinton","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.addr.2020.07.019_bb0310","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1172\/JCI5286","article-title":"Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men","volume":"103","author":"Lamarche","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0021-9150(93)90183-U","article-title":"Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase","volume":"104","author":"Mackness","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb0320","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-2275(20)33461-1","article-title":"Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1","volume":"41","author":"Navab","year":"2000","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0325","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MOL.0b013e32833bcdc1","article-title":"Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities","volume":"21","author":"Kontush","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb0330","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1194\/jlr.M600297-JLR200","article-title":"The 192R\/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux","volume":"47","author":"Gaidukov","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0335","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.bbrc.2012.11.128","article-title":"Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability","volume":"430","author":"Mishra","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2020.07.019_bb0340","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1161\/01.ATV.21.6.1023","article-title":"Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice","volume":"21","author":"Ostos","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0345","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/01.ATV.0000152613.83243.12","article-title":"Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels","volume":"25","author":"Raffai","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0350","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2011.11.031","article-title":"Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL","volume":"221","author":"Elsoe","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb0355","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1172\/JCI119369","article-title":"Mildly oxidized LDL induces an increased apolipoprotein J\/paraoxonase ratio","volume":"99","author":"Navab","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0360","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.RES.0000146031.94850.5f","article-title":"Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential","volume":"95","author":"Ribas","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0365","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/365762a0","article-title":"Protein composition determines the anti-atherogenic properties of HDL in transgenic mice","volume":"365","author":"Schultz","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.07.019_bb0370","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1194\/jlr.R400001-JLR200","article-title":"The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL","volume":"45","author":"Navab","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0375","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1006\/bbrc.1998.8803","article-title":"Lack of protection against oxidative modification of LDL by avian HDL","volume":"247","author":"Mackness","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2020.07.019_bb0380","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.carpath.2007.10.001","article-title":"Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia","volume":"17","author":"Ng","year":"2008","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.addr.2020.07.019_bb0385","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.CIR.0000023623.87083.4F","article-title":"Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice","volume":"106","author":"Tward","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0390","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/28406","article-title":"Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis","volume":"394","author":"Shih","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.07.019_bb0395","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1161\/01.CIR.0000070954.00271.13","article-title":"Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study","volume":"107","author":"Mackness","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0400","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/dna.2011.1478","article-title":"Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk","volume":"31","author":"Wang","year":"2012","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0405","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1021\/bi982258w","article-title":"A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation","volume":"38","author":"Vohl","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2020.07.019_bb0410","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.CIR.0000056523.08033.9F","article-title":"Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis","volume":"107","author":"Mertens","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0415","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jacc.2012.06.057","article-title":"Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up","volume":"60","author":"Rallidis","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb0420","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI117726","article-title":"Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein","volume":"95","author":"Watson","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0425","doi-asserted-by":"crossref","first-page":"16231","DOI":"10.1074\/jbc.272.26.16231","article-title":"Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation","volume":"272","author":"Goyal","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0430","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/CIRCULATIONAHA.105.540427","article-title":"Compromised LCAT function is associated with increased atherosclerosis","volume":"112","author":"Hovingh","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0435","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.mol.0000162318.47172.ef","article-title":"Inherited disorders of HDL metabolism and atherosclerosis","volume":"16","author":"Hovingh","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb0440","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1016\/S0021-9258(18)61335-3","article-title":"Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor","volume":"262","author":"Stafforini","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0445","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity","volume":"320","author":"Steinberg","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0450","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1074\/jbc.M211126200","article-title":"Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles","volume":"278","author":"Marathe","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0455","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1074\/jbc.M608135200","article-title":"Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides","volume":"282","author":"Kriska","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0460","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/eurheartj\/ehs148","article-title":"Phospholipase A2 enzymes and the risk of atherosclerosis","volume":"33","author":"Rosenson","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb0465","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/S0022-2275(20)41119-8","article-title":"Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein","volume":"36","author":"Christison","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0470","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.freeradbiomed.2007.12.004","article-title":"Translocation as a means of disseminating lipid hydroperoxide-induced oxidative damage and effector action","volume":"44","author":"Girotti","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0475","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00041433-200406000-00004","article-title":"Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism","volume":"15","author":"Albers","year":"2004","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb0480","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/ATVBAHA.107.145672","article-title":"Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities","volume":"27","author":"Kontush","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0485","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1161\/ATVBAHA.107.161042","article-title":"HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production","volume":"28","author":"Tolle","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0490","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1388-1981(02)00147-6","article-title":"Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?","volume":"1582","author":"Okajima","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2020.07.019_bb0495","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb0500","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cca.2015.03.038","article-title":"Apolipoprotein M","volume":"446","author":"Ren","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.addr.2020.07.019_bb0505","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1365-2362.2010.02361.x","article-title":"The versatility of HDL: a crucial anti-inflammatory regulator","volume":"40","author":"Saemann","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.addr.2020.07.019_bb0510","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/CIRCULATIONAHA.104.472886","article-title":"High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells","volume":"111","author":"Norata","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0515","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1161\/01.ATV.17.10.2158","article-title":"HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL","volume":"17","author":"Suc","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0520","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","article-title":"Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling","volume":"127","author":"Riwanto","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0525","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10557-012-6376-2","article-title":"Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection","volume":"26","author":"Somers","year":"2012","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.addr.2020.07.019_bb0530","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cvr\/cvp137","article-title":"Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion","volume":"83","author":"Hofmann","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0535","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbrc.2008.08.022","article-title":"Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia","volume":"375","author":"Vessey","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2020.07.019_bb0540","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2013.02.003","article-title":"HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity","volume":"228","author":"Frias","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107950","article-title":"RISK and SAFE signaling pathway involvement in apolipoprotein A-I-induced cardioprotection","volume":"9","author":"Kalakech","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2020.07.019_bb0550","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/89986","article-title":"High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase","volume":"7","author":"Yuhanna","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0555","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1074\/jbc.M211394200","article-title":"High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases","volume":"278","author":"Mineo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0560","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1055\/s-0038-1666870","article-title":"Elevating endogenous sphingosine-1-phosphate (S1P) levels improves endothelial function and ameliorates atherosclerosis in low density lipoprotein Receptor-deficient (LDL-R-\/-) Mice","volume":"118","author":"Feuerborn","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.addr.2020.07.019_bb0565","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/CIRCRESAHA.111.258673","article-title":"Novel biological functions of high-density lipoprotein cholesterol","volume":"111","author":"Mineo","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0570","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.ATV.19.2.378","article-title":"Inhibition of arterial thrombus formation by ApoA1 Milano","volume":"19","author":"Li","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0575","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.109.870709","article-title":"Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux","volume":"120","author":"Calkin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0580","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cvr\/cvu137","article-title":"High-density lipoprotein as a modulator of platelet and coagulation responses","volume":"103","author":"van der Stoep","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0585","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MBC.0b013e32835a083c","article-title":"High-density cholesterol and apolipoprotein AI as modifiers of plasma fibrin clot properties in apparently healthy individuals","volume":"24","author":"Zabczyk","year":"2013","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.addr.2020.07.019_bb0590","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1538-7836.2007.02311.x","article-title":"Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits","volume":"5","author":"Asselbergs","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.addr.2020.07.019_bb0595","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb0600","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0605","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER 6-HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration","volume":"55","author":"Villines","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb0610","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"H.T.C. Group","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0615","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Accelerate investigators, evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0620","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11886-018-1004-9","article-title":"HDL mimetics infusion and regression of atherosclerosis: is it still considered a valid therapeutic option?","volume":"20","author":"Karalis","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.addr.2020.07.019_bb0625","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-2275(20)38390-5","article-title":"Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins","volume":"30","author":"Cabana","year":"1989","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0630","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1002\/j.1460-2075.1989.tb08553.x","article-title":"Post-transcriptional control of negative acute phase genes by transforming growth factor beta","volume":"8","author":"Morrone","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2020.07.019_bb0635","doi-asserted-by":"crossref","first-page":"9644","DOI":"10.1016\/S0021-9258(18)67562-3","article-title":"Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition","volume":"261","author":"Coetzee","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0640","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1253\/circj.71.186","article-title":"Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes","volume":"71","author":"Kosuge","year":"2007","journal-title":"Circ. J."},{"key":"10.1016\/j.addr.2020.07.019_bb0645","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1179\/135100009X12525712409490","article-title":"A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis","volume":"14","author":"Hua","year":"2009","journal-title":"Redox Rep."},{"key":"10.1016\/j.addr.2020.07.019_bb0650","first-page":"3007","article-title":"Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk","volume":"36","author":"Zewinger","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb0655","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/01.CIR.0000115516.54550.B1","article-title":"National Heart Lung and Blood Institute, Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE)","volume":"109","author":"Johnson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0660","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.addr.2020.07.019_bb0665","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13095","article-title":"The prognostic value of serum amyloid A for long-term mortality among patients with subclinical carotid atherosclerosis","volume":"49","author":"Mayer","year":"2019","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.addr.2020.07.019_bb0670","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1073\/pnas.91.8.3186","article-title":"Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function","volume":"91","author":"Meek","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb0675","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.ATV.0000158383.65277.2b","article-title":"Serum amyloid A and lipoprotein retention in murine models of atherosclerosis","volume":"25","author":"O'Brien","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0680","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1161\/01.ATV.14.9.1480","article-title":"Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification","volume":"14","author":"Qiao","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.addr.2020.07.019_bb0685","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1440-1827.1996.tb03552.x","article-title":"Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions","volume":"46","author":"Yamada","year":"1996","journal-title":"Pathol. Int."},{"key":"10.1016\/j.addr.2020.07.019_bb0690","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1194\/jlr.M054015","article-title":"A brief elevation of serum amyloid A is sufficient to increase atherosclerosis","volume":"56","author":"Thompson","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0695","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2119\/molmed.2011.00186","article-title":"Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice","volume":"17","author":"Dong","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0700","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.001858","article-title":"Serum amyloid a facilitates early lesion development in Ldlr-\/- mice","volume":"4","author":"Krishack","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2020.07.019_bb0705","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2017.11.011","article-title":"Serum amyloid A3 is pro-atherogenic","volume":"268","author":"Thompson","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb0710","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","article-title":"Serum amyloid A - a review","volume":"24","author":"Sack","year":"2018","journal-title":"Mol. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0715","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/bbrc.2000.2143","article-title":"A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil","volume":"268","author":"Furlaneto","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2020.07.019_bb0720","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.3760\/cma.j.issn.0366-6999.20130400","article-title":"The relationship between serum amyloid A and apolipoprotein A-I in high-density lipoprotein isolated from patients with coronary heart disease","volume":"126","author":"Wang","year":"2013","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.addr.2020.07.019_bb0725","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1590\/S0074-02762011000800014","article-title":"High-density lipoprotein prevents SAA-induced production of TNF-alpha in THP-1 monocytic cells and peripheral blood mononuclear cells","volume":"106","author":"Franco","year":"2011","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.addr.2020.07.019_bb0730","doi-asserted-by":"crossref","first-page":"13257","DOI":"10.1074\/jbc.RA118.002428","article-title":"High-density lipoprotein inhibits serum amyloid A-mediated reactive oxygen species generation and NLRP3 inflammasome activation","volume":"293","author":"Shridas","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0735","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.chemphyslip.2019.03.001","article-title":"Effects of lipid composition on the structural properties of human serum amyloid A in reconstituted high-density lipoprotein particles","volume":"221","author":"Takase","year":"2019","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.addr.2020.07.019_bb0740","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1039\/C8CC01424H","article-title":"Serum amyloid A sequesters diverse phospholipids and their hydrolytic products, hampering fibril formation and proteolysis in a lipid-dependent manner","volume":"54","author":"Jayaraman","year":"2018","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.addr.2020.07.019_bb0745","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/cvr\/cvs089","article-title":"High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A","volume":"94","author":"Tolle","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0750","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1172\/JCI86401","article-title":"Serum amyloid A impairs the antiinflammatory properties of HDL","volume":"126","author":"Han","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0755","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.ATV.20.3.763","article-title":"Role of serum amyloid A during metabolism of acute-phase HDL by macrophages","volume":"20","author":"Artl","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0760","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0022-2275(20)39863-1","article-title":"Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux","volume":"36","author":"Banka","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0765","first-page":"161","article-title":"Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes","volume":"8","author":"Pruzanski","year":"1993","journal-title":"J. Lipid. Mediat."},{"key":"10.1016\/j.addr.2020.07.019_bb0770","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1161\/01.CIR.100.12.1280","article-title":"Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease","volume":"100","author":"Kugiyama","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0775","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2005.06.056","article-title":"Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes","volume":"46","author":"Mallat","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb0780","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb0785","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0021-9150(95)05604-1","article-title":"Secretory group II phospholipase A2 in human atherosclerotic plaques","volume":"118","author":"Menschikowski","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb0790","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/01.RES.86.6.707","article-title":"Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions","volume":"86","author":"Sartipy","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0795","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.ATV.19.5.1284","article-title":"Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2","volume":"19","author":"Ivandic","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0800","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1194\/jlr.M400253-JLR200","article-title":"Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition","volume":"46","author":"Ghesquiere","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0805","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MOL.0b013e32832fa14d","article-title":"Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis","volume":"20","author":"Oorni","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb0810","doi-asserted-by":"crossref","first-page":"10011","DOI":"10.1074\/jbc.M113.525717","article-title":"Proteolysis of apolipoprotein A-I by secretory phospholipase A(2): a new link between inflammation and atherosclerosis","volume":"289","author":"Cavigiolio","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0815","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2010.02.005","article-title":"Lysophospholipids: effectors mediating the contribution of dyslipidemia to calcification associated with atherosclerosis","volume":"211","author":"Camejo","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb0820","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/MOL.0b013e3282ef534f","article-title":"Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans","volume":"18","author":"Rodriguez-Lee","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb0825","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.bbalip.2015.05.007","article-title":"Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A","volume":"1851","author":"Rached","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2020.07.019_bb0830","first-page":"38","article-title":"Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2","volume":"1736","author":"Pruzanski","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2020.07.019_bb0835","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/S0022-2275(20)32470-6","article-title":"Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL","volume":"39","author":"Pruzanski","year":"1998","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0840","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/CIRCRESAHA.117.310978","article-title":"Multifunctional role of chymase in acute and chronic tissue injury and remodeling","volume":"122","author":"Dell'Italia","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0845","first-page":"49","article-title":"Identification of sites in apolipoprotein A-I susceptible to chymase and carboxypeptidase A digestion","volume":"33","author":"Usami","year":"2012","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.addr.2020.07.019_bb0850","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1194\/jlr.M200420-JLR200","article-title":"Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux","volume":"44","author":"Lee","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0855","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1096\/fj.201600508R","article-title":"Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser228 severely impairs antiatherogenic capacity","volume":"30","author":"Dinnes","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2020.07.019_bb0860","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jim.2011.04.002","article-title":"Detection of chymase-digested C-terminally truncated apolipoprotein A-I in normal human serum","volume":"369","author":"Usami","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.addr.2020.07.019_bb0865","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/ATVBAHA.115.306827","article-title":"Carboxyl-terminal cleavage of apolipoprotein A-I by human mast cell chymase impairs its anti-inflammatory properties","volume":"36","author":"Nguyen","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0870","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1194\/jlr.M077503","article-title":"Chymase released from hypoxia-activated cardiac mast cells cleaves human apoA-I at Tyr(192) and compromises its cardioprotective activity","volume":"59","author":"Kareinen","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0875","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1039\/C0MB00127A","article-title":"Protein-protein interaction heterogeneity of plasma apolipoprotein A1 in nephrotic syndrome","volume":"7","author":"Santucci","year":"2011","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.addr.2020.07.019_bb0880","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI200421109","article-title":"Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease","volume":"114","author":"Zheng","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0885","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI117342","article-title":"Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions","volume":"94","author":"Daugherty","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0890","doi-asserted-by":"crossref","first-page":"10958","DOI":"10.1074\/jbc.M114.630442","article-title":"Myeloperoxidase-mediated methionine oxidation promotes an amyloidogenic outcome for apolipoprotein A-I","volume":"290","author":"Chan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0895","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1074\/jbc.M111.337345","article-title":"Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions","volume":"287","author":"Shao","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb0900","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/CIRCRESAHA.114.303454","article-title":"Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase","volume":"114","author":"Shao","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0905","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nsmb1284","article-title":"The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction","volume":"14","author":"Wu","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0910","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1172\/JCI67478","article-title":"Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex","volume":"123","author":"Huang","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0915","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ymgme.2011.09.018","article-title":"Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies","volume":"105","author":"Zhao","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2020.07.019_bb0920","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","article-title":"Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures","volume":"96","author":"Van Lenten","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0925","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1172\/JCI42946","article-title":"Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease","volume":"121","author":"Besler","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb0930","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2018.12.002","article-title":"Brasilia Heart Study Group, Adverse interaction between HDL and the mass of myocardial infarction","volume":"281","author":"Soares","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb0935","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbalip.2011.07.013","article-title":"The HDL proteome in acute coronary syndromes shifts to an inflammatory profile","volume":"1821","author":"Alwaili","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2020.07.019_bb0940","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11154-013-9275-3","article-title":"The physiological roles of apolipoprotein J\/clusterin in metabolic and cardiovascular diseases","volume":"15","author":"Park","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.addr.2020.07.019_bb0945","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-2362.2010.02345.x","article-title":"Intravenous clusterin administration reduces myocardial infarct size in rats","volume":"40","author":"Van Dijk","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.addr.2020.07.019_bb0950","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/cvr\/cvt169","article-title":"Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome","volume":"100","author":"Gomaraschi","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0955","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clinbiochem.2014.09.001","article-title":"Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients","volume":"47","author":"Bounafaa","year":"2014","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.addr.2020.07.019_bb0960","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00395-010-0112-5","article-title":"Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease","volume":"105","author":"Sattler","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb0965","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/cvr\/cvp070","article-title":"Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection","volume":"82","author":"Sattler","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb0970","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb0975","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.86.3.839","article-title":"Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women","volume":"86","author":"The Bezafibrate Infarction Prevention (BIP) Study Group","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb0980","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/SHK.0b013e31816e30fd","article-title":"Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP","volume":"30","author":"Cazita","year":"2008","journal-title":"Shock"},{"key":"10.1016\/j.addr.2020.07.019_bb0985","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.atherosclerosis.2014.10.104","article-title":"Elevated CETP activity during acute phase of myocardial infarction is independently associated with endothelial dysfunction and adverse clinical outcome","volume":"237","author":"Carvalho","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb0990","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb0995","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb1000","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Emerging risk factors, collaboration. lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb1005","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/ATVBAHA.117.310368","volume":"38","author":"Hippe","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1015","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.117.031356","article-title":"LPA variants are associated with residual cardiovascular risk in patients receiving statins","volume":"138","author":"Wei","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1020","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2020.07.019_bb1025","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/360670a0","article-title":"Atherogenesis in transgenic mice expressing human apolipoprotein(a)","volume":"360","author":"Lawn","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.07.019_bb1030","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/clc.4960270503","article-title":"Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis","volume":"27","author":"Deb","year":"2004","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.addr.2020.07.019_bb1045","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb1055","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/ATVBAHA.117.310269","article-title":"Nonfasting triglycerides, low-density lipoprotein cholesterol, and heart failure risk: two cohort studies of 113 554 individuals","volume":"38","author":"Varbo","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/ATVBAHA.118.311999","article-title":"Highlighting residual atherosclerotic cardiovascular disease risk","volume":"39","author":"Matsuura","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1065","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1172\/JCI16751","article-title":"Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy","volume":"111","author":"Yagyu","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1070","doi-asserted-by":"crossref","first-page":"29881","DOI":"10.1074\/jbc.M114.601864","article-title":"Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure","volume":"289","author":"Liu","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb1075","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1172\/JCI10947","article-title":"A novel mouse model of lipotoxic cardiomyopathy","volume":"107","author":"Chiu","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCRESAHA.117.311307","article-title":"Mitochondrial reactive oxygen species in lipotoxic hearts induce post-translational modifications of AKAP121, DRP1, and OPA1 that promote mitochondrial fission","volume":"122","author":"Tsushima","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1085","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1172\/JCI63888","article-title":"Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes","volume":"122","author":"Russo","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208396","article-title":"Decrease in membrane phospholipids unsaturation correlates with myocardial diastolic dysfunction","volume":"13","author":"Yamamoto","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2020.07.019_bb1095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.addr.2020.07.019_bb1100","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/cvr\/cvn301","article-title":"Energy metabolism in heart failure and remodelling","volume":"81","author":"Ingwall","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/cvr\/cvv105","article-title":"Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models","volume":"106","author":"Abdurrachim","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1110","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCRESAHA.112.268128","article-title":"Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy","volume":"111","author":"Kolwicz","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1115","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1096\/fj.04-2263com","article-title":"Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart","volume":"18","author":"Sharma","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2020.07.019_bb1120","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","article-title":"Ceramide is a cardiotoxin in lipotoxic cardiomyopathy","volume":"49","author":"Park","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96203","article-title":"Increased de novo ceramide synthesis and accumulation in failing myocardium","volume":"2","author":"Ji","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.addr.2020.07.019_bb1130","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/CIRCULATIONAHA.119.039610","article-title":"Preservation of acyl coenzyme a attenuates pathological and metabolic cardiac remodeling through selective lipid trafficking","volume":"139","author":"Goldenberg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1135","article-title":"Free fatty acid effects on the atrial myocardium: membrane ionic currents are remodeled by the disruption of t-tubular architecture","volume":"10","author":"O'Connell","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2020.07.019_bb1140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.yjmcc.2009.10.004","article-title":"Palmitate attenuates myocardial contractility through augmentation of repolarizing Kv currents","volume":"48","author":"Haim","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1145","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3389\/fphys.2018.01866","article-title":"Cardiolipotoxicity, inflammation, and arrhythmias: role for interleukin-6 molecular mechanisms","volume":"9","author":"Ali","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1150","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/CIR.0000000000000574","article-title":"Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association","volume":"138","author":"Rimm","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fphys.2020.00108","article-title":"Palmitoylation: a fatty regulator of myocardial electrophysiology","volume":"11","author":"Essandoh","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/01.ATV.0000251608.09329.9a","article-title":"Role of the Toll-like receptor 4\/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages","volume":"27","author":"Suganami","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1165","doi-asserted-by":"crossref","first-page":"16979","DOI":"10.1074\/jbc.M115.646992","article-title":"Palmitoleate Reverses High Fat-induced Proinflammatory Macrophage Polarization via AMP-activated Protein Kinase (AMPK)","volume":"290","author":"Chan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb1170","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jnutbio.2006.04.003","article-title":"Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid","volume":"18","author":"Weldon","year":"2007","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.addr.2020.07.019_bb1175","doi-asserted-by":"crossref","first-page":"213S","DOI":"10.1093\/ajcn\/71.1.213S","article-title":"Fatty acid modulation of endothelial activation","volume":"71","author":"De Caterina","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.addr.2020.07.019_bb1180","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1161\/ATVBAHA.108.171736","article-title":"In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid","volume":"28","author":"Yamada","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1185","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0014-5793(00)02351-6","article-title":"Eicosapentaenoic acid (EPA) induces Ca(2+)-independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation","volume":"487","author":"Omura","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2020.07.019_bb1190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-008-6140-9","article-title":"Leukotriene signaling in atherosclerosis and ischemia","volume":"23","author":"Back","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.addr.2020.07.019_bb1195","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1172\/JCI97947","article-title":"Pro-resolving lipid mediators in vascular disease","volume":"128","author":"Conte","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1200","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3389\/fphar.2019.01022","article-title":"N-3 polyunsaturated fatty acids and the resolution of neuroinflammation","volume":"10","author":"Joffre","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"20","key":"10.1016\/j.addr.2020.07.019_bb1205","article-title":"Bioactive lipids, inflammation and chronic diseases","volume":"S0169-409X","author":"Leuti","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.07.019_bb1210","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1172\/JCI97950","article-title":"The role of non-resolving inflammation in atherosclerosis","volume":"128","author":"Kasikara","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1215","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/15548627.2015.1078958","article-title":"Activation of autophagy in macrophages by pro-resolving lipid mediators","volume":"11","author":"Prieto","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.addr.2020.07.019_bb1220","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nature05877","article-title":"Resolvin E1 and protectin D1 activate inflammation-resolution programmes","volume":"447","author":"Schwab","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.07.019_bb1225","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4049\/jimmunol.164.4.1663","article-title":"Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages","volume":"164","author":"Godson","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2020.07.019_bb1230","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.4049\/jimmunol.1100225","article-title":"Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype","volume":"187","author":"Titos","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2020.07.019_bb1235","doi-asserted-by":"crossref","first-page":"23254","DOI":"10.1073\/pnas.1907490116","article-title":"HMGB1-C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis","volume":"116","author":"Liu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb1240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/JLB.3HI0517-206RR","article-title":"Frontline science: specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome","volume":"105","author":"Lopategi","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1245","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1096\/fj.12-225615","article-title":"D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury","volume":"27","author":"Miyahara","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2020.07.019_bb1250","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1096\/fj.14-265363","article-title":"Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice","volume":"29","author":"Akagi","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2020.07.019_bb1255","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1038\/s41598-017-10441-8","article-title":"Resolution agonist 15-epi-lipoxin A4 programs early activation of resolving phase in post-myocardial infarction healing","volume":"7","author":"Kain","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2020.07.019_bb1260","first-page":"389","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"Back","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1265","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.118.311185","article-title":"Palmitoylethanolamide promotes a proresolving macrophage phenotype and attenuates atherosclerotic plaque formation","volume":"38","author":"Rinne","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1270","doi-asserted-by":"crossref","DOI":"10.3390\/nu11071672","article-title":"Plasma phospholipid fatty acids and coronary heart disease risk: a matched case-control study within the women's health initiative observational study","volume":"11","author":"Liu","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.addr.2020.07.019_bb1275","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000506","article-title":"Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis","volume":"2","author":"de Oliveira Otto","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2020.07.019_bb1280","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1161\/CIRCULATIONAHA.114.011590","article-title":"Circulating omega-6 polyunsaturated fatty acids and total and cause-specific mortality: the Cardiovascular Health Study","volume":"130","author":"Wu","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1285","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/CIRCULATIONAHA.118.038908","article-title":"Cohorts for heart aging research in genomic epidemiology, fatty acids outcomes research consortium, biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality","volume":"139","author":"Marklund","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1290","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"3","author":"Abdelhamid","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2020.07.019_bb1295","article-title":"Omega-6 fats for the primary and secondary prevention of cardiovascular disease","volume":"11","author":"Hooper","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2020.07.019_bb1300","doi-asserted-by":"crossref","unstructured":"T. Aung, J. Halsey, D. Kromhout, H.C. Gerstein, R. Marchioli, L. Tavazzi, J.M. Geleijnse, B. Rauch, A. Ness, P. Galan, E.Y. Chew, J. Bosch, R. Collins, S. Lewington, J. Armitage, R. Clarke, C. Omega-3 Treatment Trialists, Associations of Omega-3 Fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals, JAMA Cardiol., 3 (2018) 225-234.","DOI":"10.1001\/jamacardio.2017.5205"},{"key":"10.1016\/j.addr.2020.07.019_bb1305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Reduce-it investigators, cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1310","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013543","article-title":"Marine Omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants","volume":"8","author":"Hu","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2020.07.019_bb1315","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2019.10.009","article-title":"Meta-analysis comparing combined use of eicosapentaenoic acid and statin to statin alone","volume":"125","author":"Doshi","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1320","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.atherosclerosis.2012.01.006","article-title":"Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials","volume":"221","author":"Wang","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb1325","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3945\/jn.115.212282","article-title":"Higher plasma phospholipid n-3 PUFAs, but lower n-6 PUFAs, are associated with lower pulse wave velocity among older adults","volume":"145","author":"Reinders","year":"2015","journal-title":"J. Nutr."},{"key":"10.1016\/j.addr.2020.07.019_bb1330","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.amjcard.2009.01.016","article-title":"Associations of dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the Multi-Ethnic Study of Atherosclerosis [MESA])","volume":"103","author":"He","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1335","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1097\/HJH.0000000000001728","article-title":"Whole blood omega-3 fatty acid concentrations are inversely associated with blood pressure in young, healthy adults","volume":"36","author":"Filipovic","year":"2018","journal-title":"J. Hypertens."},{"key":"10.1016\/j.addr.2020.07.019_bb1340","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/ATVBAHA.117.310366","article-title":"Plasma n-3 and n-6 fatty acids are differentially related to carotid plaque and its progression: the multi-ethnic study of atherosclerosis","volume":"38","author":"Steffen","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1345","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Improve-it investigators, ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1350","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Open-label study of long-term evaluation against LDL cholesterol investigators, efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1355","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/eurheartj\/ehn346","article-title":"Discontinuation of statin therapy following an acute myocardial infarction: a population-based study","volume":"29","author":"Daskalopoulou","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb1360","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-5793(76)80996-9","article-title":"Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity","volume":"72","author":"Endo","year":"1976","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2020.07.019_bb1365","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0021-9150(80)90124-0","article-title":"Therapeutic effects of ML-236B in primary hypercholesterolemia","volume":"35","author":"Yamamoto","year":"1980","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb1370","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1008-1050","article-title":"A gift from nature: the birth of the statins","volume":"14","author":"Endo","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1375","first-page":"1","article-title":"Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes","volume":"96","author":"Bilheimer","year":"1983","journal-title":"Trans. Assoc. Am. Phys."},{"key":"10.1016\/j.addr.2020.07.019_bb1380","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.77.7.3957","article-title":"Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent","volume":"77","author":"Alberts","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb1385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1390","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.addr.2020.07.019_bb1395","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease","volume":"344","author":"The Scandinavian Simvastatin Survival Study (4S)","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb1400","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. cholesterol and recurrent events trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1405","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"G. Long-Term Intervention with Pravastatin in Ischaemic Disease Study","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1410","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Myocardial ischemia reduction with aggressive cholesterol lowering study investigators, effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb1415","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb1420","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1425","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb1430","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb1435","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Cards investigators, primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb1440","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Prosper study group. PROspective Study of Pravastatin in the Elderly at Risk, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb1445","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction investigators, intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1450","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Treating to new targets investigators, intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1455","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb1460","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/pcna guideline on the management of blood cholesterol: executive summary: a report of the american college of cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1465","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group, 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb1470","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction investigators, C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1475","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1480","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.108.813311","article-title":"Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation","volume":"119","author":"Liu","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1485","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2008.11.032","article-title":"Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study","volume":"205","author":"Ostad","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb1490","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1507\/endocrj.K10E-289","article-title":"Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients","volume":"58","author":"Kawagoe","year":"2011","journal-title":"Endocr. J."},{"key":"10.1016\/j.addr.2020.07.019_bb1495","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2011.01.062","article-title":"Pleiotropic effects of ezetimibe\/simvastatin vs. high dose simvastatin","volume":"158","author":"Pesaro","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1500","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.atherosclerosis.2012.11.028","article-title":"High-dose statin monotherapy versus low-dose statin\/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: the PANACEA study","volume":"227","author":"Westerink","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb1505","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Fourier steering committee investigators, evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1510","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Odyssey outcomes committees and investigators, alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1515","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER SPIRE, and the cholesterol treatment trialists collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb1520","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1161\/01.ATV.15.10.1652","article-title":"Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia","volume":"15","author":"Gauthier","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1525","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1530","doi-asserted-by":"crossref","first-page":"24266","DOI":"10.1074\/jbc.273.37.24266","article-title":"Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase","volume":"273","author":"Laufs","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb1535","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/21224","article-title":"Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation","volume":"399","author":"Dimmeler","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.07.019_bb1540","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1161\/01.CIR.0000065601.83526.3E","article-title":"Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-\/- mice in vivo","volume":"107","author":"Pelat","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1545","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.104.525774","article-title":"Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells","volume":"112","author":"Sen-Banerjee","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1550","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI118074","article-title":"Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines","volume":"96","author":"De Caterina","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1555","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0026-895X(24)12257-2","article-title":"Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase","volume":"59","author":"Wassmann","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.addr.2020.07.019_bb1560","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.tcm.2005.07.002","article-title":"Toward immunomodulatory and anti-inflammatory properties of statins","volume":"15","author":"Arnaud","year":"2005","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1565","doi-asserted-by":"crossref","first-page":"21926","DOI":"10.1074\/jbc.274.31.21926","article-title":"3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)","volume":"274","author":"Laufs","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb1570","first-page":"L463","article-title":"Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin","volume":"293","author":"Li","year":"2007","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.addr.2020.07.019_bb1575","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.ATV.0000068646.76823.AE","article-title":"Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages","volume":"23","author":"Luan","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1580","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.CIR.0000145170.22652.51","article-title":"Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy","volume":"110","author":"Lima","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1585","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice","volume":"31","author":"Laufs","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.addr.2020.07.019_bb1590","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb1595","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1600","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.CIR.103.2.276","article-title":"An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro","volume":"103","author":"Aikawa","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1605","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/hy1201.096541","article-title":"Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans","volume":"38","author":"Masumoto","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.addr.2020.07.019_bb1610","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00005344-200211000-00013","article-title":"Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study","volume":"40","author":"Shimokawa","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.addr.2020.07.019_bb1615","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1161\/CIRCULATIONAHA.104.510248","article-title":"Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure","volume":"111","author":"Kishi","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1620","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2005.06.003","article-title":"Fasudil Ischemic Stroke Study Group, Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial","volume":"238","author":"Shibuya","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.addr.2020.07.019_bb1625","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/clc.22118","article-title":"Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease","volume":"36","author":"Dong","year":"2013","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1630","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1016\/j.ijcard.2012.07.007","article-title":"A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome","volume":"167","author":"Dong","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1635","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.amjcard.2008.10.008","article-title":"Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event","volume":"103","author":"Rawlings","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1640","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI6842","article-title":"Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure","volume":"103","author":"Sah","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1645","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1161\/01.CIR.0000127939.16111.58","article-title":"Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice","volume":"109","author":"Hattori","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1650","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cardiores.2003.12.004","article-title":"Inhibition of Rho-kinase protects the heart against ischemia\/reperfusion injury","volume":"61","author":"Bao","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1655","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/01.CIR.0000091084.46500.BB","article-title":"Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment","volume":"108","author":"Maack","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1660","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jacc.2009.08.064","article-title":"Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation","volume":"55","author":"Adam","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1665","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0510444103","article-title":"Requirement of Rac1 in the development of cardiac hypertrophy","volume":"103","author":"Satoh","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb1670","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0014-2999(99)00282-4","article-title":"Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells","volume":"376","author":"Oi","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2020.07.019_bb1675","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0014-2999(02)02453-6","article-title":"Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin","volume":"453","author":"Nishikimi","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2020.07.019_bb1680","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.lfs.2006.04.005","article-title":"HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1","volume":"79","author":"Morikawa-Futamatsu","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2020.07.019_bb1685","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cardiores.2006.04.005","article-title":"Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy","volume":"71","author":"Custodis","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1690","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0008-6363(01)00540-5","article-title":"Impact of HMG CoA reductase inhibition on small GTPases in the heart","volume":"53","author":"Laufs","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1695","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI13350","article-title":"Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy","volume":"108","author":"Takemoto","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1700","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.RES.83.6.594","article-title":"Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy","volume":"83","author":"Kai","year":"1998","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1705","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2009.02.009","article-title":"Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction","volume":"206","author":"Vilahur","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb1710","doi-asserted-by":"crossref","first-page":"14495","DOI":"10.1073\/pnas.0601911103","article-title":"Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis","volume":"103","author":"Chang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb1715","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.yjmcc.2010.08.008","article-title":"ROCK1 plays an essential role in the transition from cardiac hypertrophy to failure in mice","volume":"49","author":"Shi","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1720","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.1074\/jbc.M604298200","article-title":"RhoA\/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis","volume":"282","author":"Del Re","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb1725","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1745-7254.2005.00105.x","article-title":"Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart","volume":"26","author":"Zheng","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2020.07.019_bb1730","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00424-009-0659-x","article-title":"RhoA-ROCK signaling is involved in contraction-mediated inhibition of SERCA2a expression in cardiomyocytes","volume":"458","author":"Vlasblom","year":"2009","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.addr.2020.07.019_bb1735","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060794","article-title":"Simvastatin attenuates cardiac fibrosis via regulation of cardiomyocyte-derived exosome secretion","volume":"8","author":"Kuo","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1740","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cardiores.2003.11.032","article-title":"Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA","volume":"61","author":"Porter","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1745","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.yjmcc.2007.05.006","article-title":"Simvastatin inhibits TNF alpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms","volume":"43","author":"Turner","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1750","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.07.019_bb1755","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1760","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2020.07.019_bb1765","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb1770","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb1775","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1780","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Clear harmony trial, safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1785","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb1790","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.addr.2020.07.019_bb1795","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1172\/JCI30060","article-title":"Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe","volume":"117","author":"Temel","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb1800","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2125.2002.01633.x","article-title":"Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin","volume":"54","author":"Kosoglou","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2020.07.019_bb1805","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Precise-Ivus investigators, impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1810","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb1815","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3389\/fphar.2019.00547","article-title":"Effects of non-statin lipid-modifying agents on cardiovascular morbidity and mortality among statin-treated patients: a systematic review and network meta-analysis","volume":"10","author":"Chaiyasothi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2020.07.019_bb1820","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","author":"Myocardial Infarction Genetics Consortium Investigators","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1825","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/DDDT.S213968","article-title":"Cost-effectiveness analysis of ezetimibe as the add-on treatment to moderate-dose rosuvastatin versus high-dose rosuvastatin in the secondary prevention of cardiovascular diseases in China: A Markov model analysis","volume":"14","author":"Yang","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.addr.2020.07.019_bb1830","first-page":"94","article-title":"Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism","volume":"78","author":"Grundy","year":"1971","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1835","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM198005293022202","article-title":"Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism","volume":"302","author":"Shepherd","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1840","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1073\/pnas.87.9.3469","article-title":"Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo","volume":"87","author":"Rudling","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb1845","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2020.07.019_bb1850","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0140-6736(92)90863-X","article-title":"Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)","volume":"339","author":"Watts","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb1855","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.CIR.69.2.313","article-title":"Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study","volume":"69","author":"Brensike","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1860","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCGENETICS.114.000952","article-title":"Effect of bile acid sequestrants on the risk of cardiovascular events: a mendelian randomization analysis","volume":"8","author":"Ross","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.addr.2020.07.019_bb1865","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/clc.4960240610","article-title":"Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia","volume":"24","author":"Davidson","year":"2001","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1870","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia","volume":"110","author":"Knapp","year":"2001","journal-title":"Am. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1875","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1185\/030079906X148436","article-title":"Lipid-lowering effects of colesevelam HCl in combination with ezetimibe","volume":"22","author":"Bays","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.addr.2020.07.019_bb1880","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2020.07.019_bb1885","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.addr.2020.07.019_bb1890","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: A Key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1895","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.addr.2020.07.019_bb1900","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in African Americans resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2020.07.019_bb1905","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1910","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.07.019_bb1915","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 Antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1920","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.0882","article-title":"Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial","author":"Gencer","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb1925","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","author":"Allahyari","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb1930","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1935","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1940","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb1945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-019-00399-6","article-title":"Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9","volume":"34","author":"German","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2020.07.019_bb1950","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fcvm.2018.00199","article-title":"Non-antibody approaches to proprotein convertase subtilisin Kexin 9 Inhibition: siRNA, antisense oligonucleotides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries","volume":"5","author":"Nishikido","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb1955","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb1960","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/CS20160403","article-title":"The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies","volume":"131","author":"Lambert","year":"2017","journal-title":"Clin. Sci."},{"key":"10.1016\/j.addr.2020.07.019_bb1965","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscl. Throm. Vas."},{"key":"10.1016\/j.addr.2020.07.019_bb1970","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb1975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.11.019","article-title":"Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages","volume":"256","author":"Adorni","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb1980","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-018-0718-x","article-title":"Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation","volume":"20","author":"Karagiannis","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.addr.2020.07.019_bb1985","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MOL.0000000000000523","article-title":"Pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 inhibitors?","volume":"29","author":"Filippatos","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb1990","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1021\/bi00232a006","article-title":"Structural properties of the microsomal triglyceride-transfer protein complex","volume":"30","author":"Wetterau","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2020.07.019_bb1995","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.addr.2020.07.019_bb2000","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev.nutr.20.1.663","article-title":"The role of the microsomal triglygeride transfer protein in abetalipoproteinemia","volume":"20","author":"Berriot-Varoqueaux","year":"2000","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.addr.2020.07.019_bb2005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb2010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/ATVBAHA.117.310675","article-title":"Expression of LDLRs (Low-density lipoprotein receptors), dyslipidemia severity, and response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibition in homozygous familial hypercholesterolemia: connecting the dots","volume":"38","author":"Santos","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb2015","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb2020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-002-0058-7","article-title":"Statins in homozygous familial hypercholesterolemia","volume":"4","author":"Marais","year":"2002","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.addr.2020.07.019_bb2025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Tesla investigators, inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb2030","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb2035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.atherosclerosis.2015.03.014","article-title":"The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial","volume":"240","author":"Stefanutti","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2020.07.019_bb2040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb2045","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/2047487317730473","article-title":"The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis","volume":"24","author":"Leipold","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb2050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"Lower investigators, LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb2055","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00018-005-4473-0","article-title":"Familial hypobetalipoproteinemia: genetics and metabolism","volume":"62","author":"Schonfeld","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.addr.2020.07.019_bb2060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb2065","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","author":"Akdim","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb2070","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb2075","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/eurheartj\/ehr148","article-title":"Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia","volume":"32","author":"Akdim","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2020.07.019_bb2080","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb2085","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2020.07.019_bb2090","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb2095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11883-015-0521-x","article-title":"Niacin therapy, HDL cholesterol, and cardiovascular disease: is the HDL Hypothesis defunct?","volume":"17","author":"Mani","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.addr.2020.07.019_bb2100","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb2105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacl.2017.10.001","article-title":"Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk","volume":"12","author":"Arsenault","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb2110","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb2115","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb2120","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"ProLiFe-Study Group, lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb2125","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","article-title":"Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells","volume":"94","author":"Marx","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2020.07.019_bb2130","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.07.019_bb2135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003877","article-title":"Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression","volume":"4","author":"Lauring","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb2140","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/ATVBAHA.108.164541","article-title":"Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins","volume":"28","author":"Lamon-Fava","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb2145","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2020.07.019_bb2150","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients","volume":"97","author":"Carpentier","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2020.07.019_bb2155","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2020.07.019_bb2160","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1161\/ATVBAHA.108.175620","article-title":"Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients","volume":"28","author":"Stroes","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb2165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0009-8981(99)00193-X","article-title":"Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments","volume":"291","author":"Lambert","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.addr.2020.07.019_bb2170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000146","article-title":"The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia","volume":"26","author":"Sacks","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb2175","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0022-2275(20)31574-1","article-title":"Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia","volume":"42","author":"Campos","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2020.07.019_bb2180","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.07.019_bb2185","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacl.2015.05.002","article-title":"The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis","volume":"9","author":"Wyler von Ballmoos","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.addr.2020.07.019_bb2190","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1373\/clinchem.2008.103234","article-title":"Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study","volume":"54","author":"Scheffer","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.addr.2020.07.019_bb2195","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Tg and Hdl Working Group of the Exome Sequencing Project","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb2200","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb2205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosissup.2018.04.074","article-title":"Apolipoprotein C-III Inhibition with volanesorsen in patients with hypertriglyceridemia (Compass): a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Gouni-Berthold","year":"2018","journal-title":"Atheroscler. Supp"},{"key":"10.1016\/j.addr.2020.07.019_bb2210","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.atherosclerosissup.2018.04.476","article-title":"Treatment with volanesorsen (Vln) reduced triglycerides and pancreatitis in patients with fcs and shtg vs placebo: results of the approach and compass studies","volume":"32","author":"Gelrud","year":"2018","journal-title":"Atheroscler. Supp"},{"key":"10.1016\/j.addr.2020.07.019_bb2215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb2220","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2020.07.019_bb2225","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jacbts.2019.05.008","article-title":"Angiopoietin-like 3: from discovery to therapeutic gene editing","volume":"4","author":"Wang","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.addr.2020.07.019_bb2230","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2020.07.019_bb2235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.07.019_bb2240","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome","volume":"14","author":"Meyers","year":"2015","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.addr.2020.07.019_bb2245","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/dom.12221","article-title":"Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial","volume":"16","author":"Denison","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2020.07.019_bb2250","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/jcph.509","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects","volume":"55","author":"Meyers","year":"2015","journal-title":"J. Clin. Pharmacol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20301034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20301034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:01:05Z","timestamp":1759208465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X20301034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":450,"alternative-id":["S0169409X20301034"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2020.07.019","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2020.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}